Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

Video

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma (DLBCL).

No biomarkers currently can inform whether a patient will respond to frontline chemoimmunotherapy. CAR T-cell therapy may provide a welcome alternative that can spare patients with DLBCL the toxicities associated with chemotherapy, Ghosh says. Moreover, patients could potentially obtain a long remission with a single infusion of CAR T-cell therapy vs multiple cycles of chemotherapy, Ghosh adds.

However, frontline treatment with traditional chemoimmunotherapy has demonstrated long-term remissions in around 60% of patients with DLBCL, says Ghosh. As such, demonstrating that CAR T-cell therapy is an effective frontline option could be difficult because the standard of care already elicits high response rates with potential curative benefit, Ghosh explains. Ultimately, a randomized clinical trial comparing chemoimmunotherapy with CAR T-cell therapy is warranted, concludes Ghosh.

Related Videos
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
© 2024 MJH Life Sciences

All rights reserved.